标题：Research Grade Nirsevimab尼塞韦单抗,AntibodySystem Laboratories
链接：https://www.antibodysystem.com/product/640.html
名称：Research Grade Nirsevimab尼塞韦单抗
别名：Nirsevimab 尼塞韦单抗，MEDI-8897, MEDI8897, Human Respiratory Syncytial Virus (HRSV)
CAS: 1989556-22-0
货号：DVV02802
适用物种：HRSV-A
寄主物种：Humanized
形式：Liquid
纯度：>95%
克隆性：Monoclonal
同种型：IgG1, kappa
应用：Research Grade Biosimilar
UniProt：P03420
用途范围：仅用于科研
靶点：F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1
储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
免费热线：027-65279366 /18108604356
QQ：2663991332
咨询邮箱：products@biolabreagent.com
选购商城：https://www.antibodysystem.com
微信公众平台：佰乐博生物Biolab Reagents
参考文献：
Nirsevimab: First Approval. PMID: 36577878
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. PMID: 35235726
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. PMID: 32730699
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. PMID: 35235733
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. PMID: 37018470
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. PMID: 36634694
Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. PMID: 38157500
Nirsevimab-alip. PMID: 37675981
Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP). PMID: 37743207
Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV). PMID: 34937485
Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. PMID: 37095249
The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis. PMID: 37082704
Nirsevimab: A Review. PMID: 38484270
Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data. PMID: 36940703
Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants. PMID: 36922390
Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. PMID: 37616235
Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model. PMID: 35968866
Formulary Drug Reviews: Nirsevimab. PMID: 38450347
Antibodies to watch in 2023. PMID: 36472472
Nirsevimab: a promising therapy for RSV. PMID: 35544094
Nirsevimab-resistant respiratory syncytial virus strains are rare but there. PMID: 36940704
Nirsevimab brings breakthrough in the prevention of respiratory syncytial virus infection in infants - Importance of design. PMID: 37324599
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials. PMID: 37468530
Development of mRNA vaccines against respiratory syncytial virus (RSV). PMID: 36280532
Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection. PMID: 37901217
Nirsevimab (Beyfortus) for prevention of severe RSV disease in young children. PMID: 37682698
Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease. PMID: 37466917
RSV Prevention in All Infants: Which Is the Most Preferable Strategy? PMID: 35572550
Single-dose nirsevimab prevents RSV infection. PMID: 33342497
Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study. PMID: 38026446
Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper. PMID: 34456918
Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales. PMID: 36328884
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. PMID: 38457312
Nirsevimab and other strategies for the prevention of RSV infection. PMID: 37739824
Cost-Effectiveness of Nirsevimab for the Prevention of Respiratory Syncytial Virus Infection in Infants: CADTH Health Technology Review. PMID: 38096341
Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age. PMID: 38070539
US nirsevimab shortage forces drug rationing as RSV rates increase. PMID: 37944545
